



# HETERO LABS LIMITED (UNIT-II)

(Formulations Division)

## CERTIFICATE OF ANALYSIS

<b>Product Name: LEDIFOS (Ledipasvir 90mg and Sofosbuvir 400mg Tablets)</b>			
<b>Product Code</b>	4013077	<b>A.R. No.</b>	H5FP19002056
<b>Specification ID</b>	FPS/B-3007107-1-02	<b>Batch No.</b>	31172446
<b>Mfg. Date</b>	05/2019	<b>Batch Size</b>	1.0 Lac.
<b>Exp. Date</b>	04/2021	<b>Date Of Release</b>	27-05-2019

S. No.	TEST	RESULT	SPECIFICATION
1	<b>Description</b>	Brown coloured, capsule shaped, bevel biconvex film coated tablets debossed with 'H' on one side and 'L18' on other side.	Brown coloured, capsule shaped, bevel biconvex film coated tablets debossed with 'H' on one side and 'L18' on other side.
2	<b>Identification (By HPLC)</b>	The retention time of the major peak in the chromatogram of the sample solution corresponds to that in the chromatogram of the standard solution, as obtained in the assay.	The retention time of the major peak in the chromatogram of the sample solution should correspond to that in the chromatogram of the standard solution, as obtained in the assay.
3	<b>Average weight</b>	1029.57 mg	1025.00mg $\pm$ 3.0% (994.25mg to 1055.75mg)
4	<b>Uniformity of weight</b>	Highest : 1.16 % Lowest:-0.93 %	$\pm$ 5% of Average weight
5	<b>Water content (By KF)</b>	3.40 %w/w	Not more than 5.0%w/w
6	<b>Uniformity of Content (By HPLC) Content of Ledipasvir</b>	Min. : 98.3 % Max. : 99.4 % Average::99.0 %	Not less than 85.0% and Not more than 115.0% of average content.
7	<b>Dissolution (By HPLC)</b>		
7.1	<b>Ledipasvir</b>	Tablet 1- : 97.7 % Tablet 2- : 95.6 % Tablet 3- : 93.7 % Tablet 4- : 93.9 % Tablet 5- : 97.1 % Tablet 6- : 97.1 % Average::95.8 %	Not less than 75 % (D) of labeled amount of Ledipasvir should dissolve in 30 minutes.
7.2	<b>Sofosbuvir</b>	Tablet 1- : 86.9 % Tablet 2- : 85.0 %	Not less than 75 % (D) of labeled amount of Sofosbuvir should dissolve

Remarks: APPROVED (Sample Conforms to above Specification)

<b>Checked By</b>	MANU.RAJ	<b>Approved By</b>	D.S.N.Reddy
<b>Date</b>	27-05-2019 17:26	<b>Date</b>	27-05-2019 17:31
<b>Printed by: D.S.N.Reddy</b>		<b>Printed on: 27-05-2019 17:49</b>	
<b>Copy No.: 1</b>		<b>Page No.: 1 of 2</b>	
<b>Note : This document has been generated electronically and is valid without signature.</b>			
<b>CNo: C100002148</b>			



# HETERO LABS LIMITED (UNIT-II)

(Formulations Division)

## CERTIFICATE OF ANALYSIS

<b>Product Name: LEDIFOS (Ledipasvir 90mg and Sofosbuvir 400mg Tablets)</b>			
<b>Product Code</b>	4013077	<b>A.R. No.</b>	H5FP19002056
<b>Specification ID</b>	FPS/B-3007107-1-02	<b>Batch No.</b>	31172446
<b>Mfg. Date</b>	05/2019	<b>Batch Size</b>	1.0 Lac.
<b>Exp. Date</b>	04/2021	<b>Date Of Release</b>	27-05-2019

		Tablet 3- : 96.7 % Tablet 4- : 97.0 % Tablet 5- : 84.7 % Tablet 6- : 84.7 % Average::89.1 %	in 30 minutes.
8	<b>Related Substances (By HPLC)</b>		
8.1	<b>Sofosbuvir Related compound -01</b>	0.00 %	Not more than 0.50%
8.2	<b>Ledipasvir Related compound -04</b>	0.08 %	Not more than 1.0%
8.3	<b>Max. single Unknown Impurity</b>	0.18 %	Not more than 0.50%
8.4	<b>Total Impurities</b>	0.44 %	Not more than 2.0%
9	<b>Assay (By HPLC) Each film coated tablet contains</b>		
9.1	<b>Ledipasvir (C49H54F2N8O6), in mg</b>	91.33 mg	Not less than 85.5mg and Not more than 94.5mg
9.2	<b>(%) Labeled amount</b>	101.5 %	Not less than 95.0 and Not more than 105.0
9.3	<b>Sofosbuvir (C22H29 FN3O9P) in mg</b>	397.34 mg	Not less than 380.0mg and Not more than 420.0mg
9.4	<b>(%) Labeled amount</b>	99.3 %	Not less than 95.0 and Not more than 105.0

<b>Remarks: APPROVED (Sample Conforms to above Specification)</b>			
<b>Checked By</b>	MANU.RAJ	<b>Approved By</b>	D.S.N.Reddy
<b>Date</b>	27-05-2019 17:26	<b>Date</b>	27-05-2019 17:31
<b>Printed by: D.S.N.Reddy</b>		<b>Printed on: 27-05-2019 17:49</b>	
<b>Copy No.: 1</b>		<b>Page No.: 2 of 2</b>	
<b>Note : This document has been generated electronically and is valid without signature.</b>			
<b>CNo: C100002148</b>			